Ontology highlight
ABSTRACT: Objective
MicroRNA-205 (miRNA-205) was revealed as an attractive prognostic tumour biomarker in recent studies. However, the results of different studies have been inconsistent. We conducted a meta-analysis to elucidate the precise predictive value of miRNA-205 in various human malignant neoplasms.Design
Meta-analysis.Data sources
Qualified studies were identified up to 5 June 2014 by performing online searches in PubMed, EMBASE and Web of Science, and additional quality evaluations.Participants
Seventeen eligible studies with 4827 patients were ultimately enrolled in this meta-analysis.Outcome measures
The heterogeneity between studies was assessed using I(2) statistics. Pooled HRs with 95% CIs for patient survival and disease recurrence were calculated to investigate the correlation between miRNA-205 expression and cancer prognosis.Results
Our results indicate that elevated miRNA-205 was significantly associated with enhanced overall survival in the breast cancer subgroup (HR=0.78, 95% CI 0.67 to 0.91) and superior disease-free survival/recurrence-free survival in the adenocarcinoma subgroup (HR=0.68, 95% CI 0.49 to 0.94).Conclusions
miRNA-205 is a promising biomarker for predicting the recurrence and progression of patients with adenocarcinomas or breast cancer. Owing to its complex roles, further relevant studies are warranted.
SUBMITTER: Zhang JY
PROVIDER: S-EPMC4305071 | biostudies-literature | 2015 Jan
REPOSITORIES: biostudies-literature
Zhang Jia-Yi JY Sun Meng-Yan MY Song Ning-Hong NH Deng Zhong-Lei ZL Xue Chun-Yu CY Yang Jie J
BMJ open 20150122 1
<h4>Objective</h4>MicroRNA-205 (miRNA-205) was revealed as an attractive prognostic tumour biomarker in recent studies. However, the results of different studies have been inconsistent. We conducted a meta-analysis to elucidate the precise predictive value of miRNA-205 in various human malignant neoplasms.<h4>Design</h4>Meta-analysis.<h4>Data sources</h4>Qualified studies were identified up to 5 June 2014 by performing online searches in PubMed, EMBASE and Web of Science, and additional quality ...[more]